

Cite this: *RSC Adv.*, 2018, 8, 25941

Photostability and antioxidant activity studies on the inclusion complexes of *trans*-polydatin with β -cyclodextrin and derivatives†

Shujing Li,^{id}*^{ab} Li Yuan,^{ab} Bing Zhang,^{*c} Wei Zhou,^{ab} Xinrui Wang^{ab} and Dongsheng Bai^{ab}

The inclusion complexes of *trans*-polydatin and three cyclodextrins (CDs), namely β -cyclodextrin (β -CD), methyl- β -cyclodextrin (Me- β -CD) and (2-hydroxy) propyl- β -cyclodextrin (HP- β -CD) were prepared. The effects of the inclusion behavior of *trans*-polydatin with three kinds of CDs were investigated in both solution and the solid state with the following methods: phase-solubility, X-ray diffraction (XRD), thermogravimetric analysis (TG), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM), proton nuclear magnetic resonance (¹H-NMR) and two-dimensional rotational frame nuclear overhauser effect spectroscopy (2D ROESY). The results indicated that *trans*-polydatin formed a 1 : 1 stoichiometric inclusion complex with CDs. Meanwhile, the solubility and thermal stability of the inclusion complexes were improved after encapsulating by CDs. Furthermore, the photostability of *trans*-polydatin was enhanced after forming the inclusion complexes. The antioxidant activities results showed that the antioxidant performance of the inclusion complexes was enhanced in comparison to the native *trans*-polydatin. Therefore, it can be a potentially promising way to promote its drug bioavailability or phytochemical preparations.

Received 5th June 2018

Accepted 10th July 2018

DOI: 10.1039/c8ra04778b

rsc.li/rsc-advances

Introduction

Polydatin (3,4',5-trihydroxystilbene-3- β -mono-D-glucoside, Fig. 1a) is the major component of *Polygonum cuspidatum* root, and is widely used in medicine and health products.^{1–3} Polydatin has been shown to possess biological activities, which include anti-platelet aggregation,⁴ anti-cancer effects,⁵ anti-oxidative activities,^{6,7} and anti-inflammatory activity.⁸ It also has multiple activities in the cardiovascular and hematological system and can protect myocardial cells injured by deprivation of oxygen and glucose.^{9,10} Even though polydatin has a vast range of health benefits, the practical biological application of polydatin is limited due to its poor water solubility and stability.¹¹ Interestingly, these problems can be solved by complexation with cyclodextrins (CDs) in aqueous solutions. Cyclodextrins (CDs) are cyclic oligosaccharides consisting of (α -1,4)-linked glucopyranose units with a hydrophobic cavity and a hydrophilic outer surface.¹² The truncated cone-shaped

structure of CDs enables them to enclose the hydrophobic molecules to form the inclusion complex.^{13–17} The CDs and their inclusion complexes are always used as delivery systems in the drug, food, cosmetics, packaging, and textile industries.^{18,19} β -Cyclodextrin (β -CD) is the most commonly used in pharmaceutical formulations due to its non-toxicity, biodegradability and reasonable cost. However, the application of unmodified β -CD is limited owing to its poor water solubility. Therefore, modified β -CDs have been synthesized and used, such as methylated- β -cyclodextrin (Me- β -CD) and (2-hydroxy) propyl- β -cyclodextrin (HP- β -CD).^{20,21}

Recently, An *et al.* investigated the inclusion behavior of HP- β -CD with polydatin in solution and its analytical application.²²




Fig. 1 Chemical structure of *trans*-polydatin (a) and *cis*-polydatin (b).

^aBeijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University, Beijing 100048, PR China. E-mail: lishujing@th.btbu.edu.cn

^bDepartment of Chemistry, School of Science, Beijing Technology and Business University, Beijing 100048, PR China

^cTechnical Institute of Physics and Chemistry, Chinese Academy of Science, Beijing 100190, PR China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra04778b

Zhang and Liu reported the inclusion complex of polydatin with β -CD, γ -CD and 6-*O*- α -maltosyl- β -CD, their physicochemical characteristics has been studied and characterized.^{23,24} Although these studies have demonstrated the feasibility of obtaining inclusion complexes with polydatin, none of them evaluated the photostability and antioxidant activities of polydatin with different CDs. Polydatin exists in two isomeric forms, *trans*-polydatin (Fig. 1a) and *cis*-polydatin (Fig. 1b); the former has been implicated as a bioactive material of major benefit to humans. However *trans*-polydatin is highly unstable to UV light and readily isomerizes to the *cis*-polydatin form. In this work we are aimed to overcome the isomerization of the highly valuable *trans*-polydatin by using the extraordinary properties of CDs to form host-guest inclusion complexes and evaluate the antioxidant activities of the inclusion complexes. The inclusion complexes were prepared by the freeze-drying method and were further characterized by XRD, TG, DSC, SEM, ¹H-NMR and 2D ROESY. The photostability of *trans*-polydatin before and after encapsulating by CDs were characterized by UV-vis spectra. Meanwhile, the antioxidant activities of *trans*-polydatin and the inclusion complexes were also investigated by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity assay.

Experimental

Materials

trans-Polydatin (>99%), potassium ferricyanide (K₃Fe(CN)₆), trichloroacetic acid (TCA), ferric chloride (FeCl₃) were obtained from Aladdin Industrial Corporation (Shanghai, China); β -cyclodextrin (β -CD, $M_w = 1135 \text{ g mol}^{-1}$), methyl- β -cyclodextrin (Me- β -CD, $M_w = 1310 \text{ g mol}^{-1}$), average degree of substitution (DS = 12.5), (2-hydroxy) propyl- β -cyclodextrin (HP- β -CD, $M_w = 1375 \text{ g mol}^{-1}$), average degree of substitution (DS = 4.2) were purchased from Seebio Biotech, Inc. (Shanghai, China); 1,1-diphenyl-2-picryl-hydrazyl (DPPH) was supplied by TCI (Shanghai) Development Co., Ltd.

Preparation of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD and *trans*-polydatin-HP- β -CD inclusion complexes

trans-Polydatin (0.3 mmol) was dissolved in 40 mL ethanol, CDs (β -CD, Me- β -CD, HP- β -CD, 0.3 mmol) were dissolved in 160 mL water, and then the CDs solutions were added to the *trans*-polydatin solution. The mixture was sealed and stirred for 48 h. After evaporating the ethanol from the reaction mixture, the uncomplexed *trans*-polydatin was filtered through a 0.45 μm hydrophilic membrane filter. The filtrate was frozen at -40°C for 24 h and then lyophilized. The resultant powders collected as the *trans*-polydatin-CDs complexes.

The encapsulation efficiency of *trans*-polydatin was determined with the modified procedure described by Li *et al.*²⁵ In brief, the *trans*-polydatin-CDs inclusion complex was dispersed in 50% methanol solution and incubated at 60°C for 1 h. After filtration, the absorbance of filtrate was determined by UV-vis spectrum to calculate the included *trans*-polydatin in the inclusion complex. The encapsulation efficiency (E_r) were obtained using following equations:

$$E_r = \frac{M_i}{M_t} \times 100\%$$

where, M_i is the included *trans*-polydatin content in the inclusion complex, and M_t is the total *trans*-polydatin content in reaction system.

The E_r of *trans*-polydatin- β -CD was calculated to be $74.83 \pm 1.92\%$. The E_r of *trans*-polydatin-HP- β -CD was calculated to be $77.31 \pm 2.41\%$. The E_r of *trans*-polydatin-Me- β -CD was calculated to be $79.12 \pm 1.67\%$.

Preparation of *trans*-polydatin/ β -CD, *trans*-polydatin/Me- β -CD and *trans*-polydatin/HP- β -CD physical mixture

The physical mixture was prepared by mixing the powders in a 1 : 1 molar ratio of polydatin and CDs in an agate mortar.

Phase-solubility study

Phase-solubility studies were performed according to the method reported by Higuchi and Connors.²⁶ An excess amount of *trans*-polydatin was added to 10 mL of aqueous solution containing different concentrations of β -CD, Me- β -CD, and HP- β -CD (from 0 mM to 10.0 mM). The mixtures were vigorously shaken with a shaking rate at 120 rpm in water bath for 72 h at 25°C . After reaching equilibrium, the samples were filtered through a 0.45 μm hydrophilic membrane filter. All samples were prepared in triplicate. The concentration of *trans*-polydatin in the filtrate was determined by a CARY-60 spectrophotometer (Varian, America). The phase-solubility profiles were obtained by plotting the solubility of *trans*-polydatin vs. the concentration of β -CD, Me- β -CD, or HP- β -CD. The apparent stability constants (K_s) were calculated from phase-solubility diagrams according to the following equation:

$$K_s = \frac{\text{Slope}}{S_0(1 - \text{Slope})} \quad (1)$$

where S_0 is the solubility of *trans*-polydatin at 25°C in the absence of cyclodextrins and slope means the corresponding slope of the phase-solubility diagrams.

Powder X-ray diffraction (XRD)

Monochromatic Cu K α radiation (wavelength = 1.54056 \AA) was produced by D/MAX 2500V/PC X-ray diffractometer (Rigaku Americas Corporation, Japan). The powders of samples were packed tightly in a rectangular aluminum cell. The samples were exposed to the X-ray beam. The scanning regions of the diffraction angle, 2θ , were $5\text{--}50^\circ$. Duplicate measurements were made at ambient temperature. Radiation was detected with a proportional detector.

Thermal analyses (TG) and differential scanning calorimetry (DSC)

TG and DSC measurements were performed with a DTG-60AH (Shimadzu, Japan) instrument, at a heating rate of $10^\circ\text{C min}^{-1}$ from 30°C to 400°C in a dynamic nitrogen atmosphere (flow rate = 70 mL min^{-1}).



Scanning electron microscopy (SEM)

SEM photographs were determined on a TESCAN VEGA II. The powders were previously fixed on a brass stub using double-sided adhesive tape and then were made electrically conductive by coating, in a vacuum with a thin layer of gold for 30 s and at 20 W.

¹H-NMR and 2D NMR

The ¹H-NMR and 2D ROESY spectra were all recorded on a BRUKER AVANCE 600 NMR spectrometer at 25 °C. Deuterium oxide (D₂O) was used as the solvent. Chemical shifts were referenced to the solvent values (4.70 ppm for HOD).

Photostability study of *trans*-polydatin and inclusion complexes

The native *trans*-polydatin and *trans*-polydatin-CDs inclusion complexes (6×10^{-5} mol L⁻¹) were used for UV irradiation analysis. Aliquots of 20 mL were added to a 6 cm diameter Petri dish and placed 20 cm from the UV light source. The photo intensity is 21.0 W cm⁻². The solutions were irradiated at 25 °C for 1.5–2 h and monitored by UV-vis spectrophotometer.

Antioxidant and free-radical scavenging activities

Reducing power assay. The reducing power (RP) of the *trans*-polydatin-CDs inclusion complexes and native *trans*-polydatin were investigated according to the method of Ma *et al.*²⁷ The different concentrations of the samples with 2.0 mL of phosphate buffer (0.2 M, pH 6.6) and 2.0 mL of K₃Fe(CN)₆ (1%, w/v). In the next step, the mixtures were incubated at 50 °C for 20 min, and then rapidly cooled. 2.0 mL of TCA solution (10.0%, w/v) was added to the mixture. 2.0 mL of upper layer of the solution was taken out and mixed with 2.0 mL of deionized water and 0.4 mL of FeCl₃ (0.1% w/v). The absorbance after 10 min reaction was measured using an UV-vis spectrophotometer at 700 nm.

DPPH radical-scavenging capacity. DPPH free-radical scavenging by the *trans*-polydatin-CDs inclusion complexes and native *trans*-polydatin were investigated according to the method of Hatano *et al.*²⁸ Briefly, DPPH solutions (2.0 mL) in ethanol (1×10^{-4} mol L⁻¹) and 2.0 mL of tested samples with various concentrations were mixed in the tubes. Then, the mixture was incubated for 60 min in the dark at 30 ± 1 °C. The absorbance was measured at 517 nm in CARY-60 UV-vis spectrometer. Lower absorbance of the reaction mixture indicated higher free radical scavenging activity. The DPPH scavenging effect (KD) was calculated using the following equation:

$$K_D = \left(\frac{A_0 - (A_i - A_j)}{A_0} \right) \times 100\% \quad (2)$$

where A_0 is the absorbance of 2.0 mL DPPH solution and 2.0 mL sample solvent, A_i is the absorbance of 2.0 mL DPPH solution and 2.0 mL sample solution and A_j is the absorbance of 2.0 mL sample solution and 2.0 mL ethanol.

Statistical analysis. All analytical experiments were carried out in three replicates and the results presented as a mean \pm standard deviation (SD). Analysis of variance (ANOVA) procedure followed by Duncan's test using SPSS 13 (SPSS Inc., Chicago, Illinois, USA) software.

Results and discussion

Phase-solubility study

Phase-solubility analysis of *trans*-polydatin with β -CD, Me- β -CD, and HP- β -CD was performed by the method of Higuchi and Connors in aqueous solution at 25 °C.²⁶ The phase-solubility diagram is a widely useful technique for evaluation of the inclusion effect of CDs with poor water-soluble molecules and determination of the stability constants (K_s). As shown in Fig. 2, the aqueous solubility of *trans*-polydatin increased linearly with increasing CDs concentration within the studied concentration range. Based on Higuchi and Connors's theory, these three linear host-guest correlations can be classified as A_L type, indicating that a 1 : 1 stoichiometry of the complexes between *trans*-polydatin and the three different CDs studied. The calculated apparent stability constant (K_s , M⁻¹) of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD and *trans*-polydatin-HP- β -CD, was 798 M⁻¹, 1106 M⁻¹, and 1308 M⁻¹, respectively. The higher apparent stability constant of *trans*-polydatin-Me- β -CD and *trans*-polydatin-HP- β -CD can be attributed to the opening enlargement of native β -CD and destruction of the strong intramolecular hydrogen bond network by the methyl and hydroxypropyl substitutions which lets guest molecules access the CD cavity easily and give a higher stability constant. The findings states that CDs increase the binding capacity for flavonoids have been previously reported.^{29,30} Additionally, the solubility of *trans*-polydatin was significantly increased (6.4-fold, 7.9-fold, and 9.0-fold at 10 mM of β -CD, Me- β -CD, and HP- β -CD) compared to the absence of CDs, which indicated the solubilizing potential for *trans*-polydatin by CDs.




Fig. 2 Phase-solubility diagrams of *trans*-polydatin with β -CD, Me- β -CD, or HP- β -CD at 25 °C.






Fig. 3 XRD patterns: (A) (a) *trans*-polydatin, (b) β -CD, (c) *trans*-polydatin/ β -CD physical mixture, (d) *trans*-polydatin- β -CD inclusion complex; (B) (a) *trans*-polydatin, (b) Me- β -CD, (c) *trans*-polydatin/Me- β -CD physical mixture, (d) *trans*-polydatin-Me- β -CD inclusion complex; (C) (a) *trans*-polydatin, (b) HP- β -CD, (c) *trans*-polydatin/HP- β -CD physical mixture, (d) *trans*-polydatin-HP- β -CD inclusion complex.

XRD studies

XRD is an effective method for the analysis of CDs and their inclusion complex in the powder or microcrystalline state.^{31,32} The formation of an inclusion complex between cyclodextrin and a crystalline guest mean that the latter would no longer exist in the crystalline state and, consequently, the diffraction pattern of the complex would not be a simple superposition of those two components. As indicated in Fig. 3, the XRD patterns of *trans*-polydatin and β -CD displayed numerous sharp peaks characteristic of its crystallinity, whereas that of Me- β -CD and HP- β -CD showed two broad peaks, consistent with its amorphous nature. The XRD of the physical mixture of *trans*-polydatin and CDs was a superposition of the patterns of the components, confirming that no chemical association was occurred between *trans*-polydatin and CDs, and both kept their original physical characteristics. In contrast, XRD of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex are amorphous and show halo patterns, indicating the interaction between *trans*-polydatin and β -CD (Me- β -CD, or HP- β -CD).

Thermal analysis

The thermal properties of *trans*-polydatin, CDs, and *trans*-polydatin-CDs inclusion complexes were studied by TG methods³³ (see ESI Fig. S1–S3†). A systematic analysis of the TG curves showed that *trans*-polydatin decomposes at ca. 270 °C, β -CD at ca. 298 °C, Me- β -CD at ca. 290 °C, and HP- β -CD at ca. 304 °C. In contrast, the decomposition temperature of the *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex is ca. 281 °C, 288 °C, and 298 °C. These results confirm the formation of the *trans*-polydatin-CDs inclusion complexes. Furthermore, the thermal stability of *trans*-polydatin was enhanced after encapsulating by CDs.

DSC gave further information about the thermal properties of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex. As shown in Fig. 4, *trans*-polydatin displayed one sharp endothermic peak at 230 °C. In contrast, the DSC curves of β -CD, Me- β -CD, and HP- β -CD had an endothermic peak at 325 °C, 339 °C, and 323 °C, respectively.




Fig. 4 DSC thermograms: (A) (a) *trans*-polydatin, (b) β -CD, (c) *trans*-polydatin/ β -CD physical mixture, (d) *trans*-polydatin- β -CD inclusion complex; (B) (a) *trans*-polydatin, (b) Me- β -CD, (c) *trans*-polydatin and Me- β -CD physical mixture, (d) *trans*-polydatin-Me- β -CD inclusion complex; (C) (a) *trans*-polydatin, (b) HP- β -CD, (c) *trans*-polydatin/HP- β -CD physical mixture, (d) *trans*-polydatin-HP- β -CD inclusion complex.

The DSC thermogram of the physical mixture is basically a combination of two components, with the *trans*-polydatin peaks only faintly observable due to the lower proportions it had in the physical mixture. However, in the DSC curves of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex, the endothermic peaks were shifted to 354 °C, 357 °C, and 354 °C, suggesting that an inclusion structure was formed between the host guest molecules. These results further confirm the formation of inclusion complex between *trans*-polydatin and CDs.³⁴

SEM studies

SEM is a qualitative method used to study the structural aspects of the materials.^{35,36} Fig. 5 shows the SEM photographs of *trans*-polydatin, HP- β -CD, their physical mixture, and inclusion complex. Pure *trans*-polydatin existed in columnar crystal with medium dimensions and HP- β -CD appears as a spherical shape with cavity structures. The physical mixture of *trans*-polydatin with CDs revealed the characteristic crystals of *trans*-polydatin and the spheres of HP- β -CD both existed separately, indicating the two components exist in their original individual forms. In contrast, the *trans*-polydatin-CDs inclusion complex appeared as plate-like structure crystal and was quite different from the sizes and shapes of *trans*-polydatin and CDs, which confirms the formation of the inclusion complex between *trans*-polydatin and HP- β -CD. In similar test, the *trans*-polydatin- β -CD and *trans*-polydatin-Me- β -CD appeared to be quite different from the sizes and shapes of β -CD, Me- β -CD and *trans*-polydatin, respectively, which are a strong indication of inclusion complex formation (see in the ESI Fig. S4 and S5†).

¹H-NMR and 2D NMR

Further evidence supporting the formation of the inclusion complex was obtained by ¹H-NMR, which has proved to be the most direct evidence in explaining the host-guest interaction of CDs and guest molecules.^{37,38} We measured the ¹H-NMR spectra of the CDs and the inclusion complexes of *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD in D₂O






Fig. 5 Scanning electron microphotographs: (A) *trans*-polydatin, (B) HP-β-CD, (C) *trans*-polydatin/HP-β-CD physical mixture, (D) *trans*-polydatin-HP-β-CD inclusion complex.

(see ESI Fig. S6–S11†). The ^1H -NMR spectra of the inclusion complexes showed all of the expected proton signals of *trans*-polydatin and CDs, in agreement with the formation of the inclusion complex.

To understand the detailed inclusion fashion of *trans*-polydatin-β-CD, *trans*-polydatin-Me-β-CD, and *trans*-polydatin-HP-β-CD, 2D ROESY NMR spectra were also measured. As shown in Fig. 6, the 2D ROESY NMR spectrum of *trans*-polydatin-HP-β-CD showed strong correlation signals between the inner H-3 and H-5 protons of the HP-β-CD and the *trans*-polydatin protons. The spectrum exhibited strong correlation signals between the H-3 protons of the HP-β-CD and the H-7,8 of *trans*-polydatin. Meanwhile, the correlation signals were also observed between H-5 protons of the HP-β-CD and H-11, 13 protons of *trans*-polydatin. However, the spectrum did not show any significant correlation signals between the H-5 proton of the HP-β-CD and




Fig. 6 ROESY spectrum of the *trans*-polydatin-HP-β-CD inclusion complex in D_2O at 25°C .




Fig. 7 Possible inclusion mode of the *trans*-polydatin-HP-β-CD inclusion complex.

the H-7,8 protons of *trans*-polydatin. These data indicate that the HP-β-CD selectively includes the *trans*-polydatin from the wide rim side to form the inclusion complex. It was also shown that *trans*-polydatin should be encapsulated in the β-CD and Me-β-CD cavities in a similar way (see ESI Fig. S12 and 13†). A study reported by Zhang *et al.*²⁴ indicated that the formation of the inclusion complex between *trans*-polydatin with β-CD and γ-CD also occurred through the aromatic ring of *trans*-polydatin into the CDs cavity, which is similar to our findings. Based on these observations, together with the 1 : 1 stoichiometry, we deduced the possible inclusion modes of *trans*-polydatin with CDs, as illustrated in Fig. 7.

Photostability in free and complex form

In order to examine the photostability of the inclusion complexes, the solutions of *trans*-polydatin ($p < 0.05$) and *trans*-polydatin-CDs ($p < 0.05$) at the concentration of $6 \times 10^{-5} \text{ mol L}^{-1}$ were exposed to UV light. Monitoring the reduction of *trans*-polydatin concentration during the irradiating time it was obtained using UV-vis method. The effect of CDs on the photostability of *trans*-polydatin is illustrated in Fig. 8. After comparison of the photoisomerization profiles obtained for *trans*-polydatin and its complexes, it can be concluded that the CDs had a significant effect on the rate of *trans*-polydatin photoisomerization. After 180 min irradiation, the content of *trans*-polydatin was decreased for 54%, while the content of *trans*-polydatin in *trans*-polydatin-β-CD, *trans*-polydatin-Me-β-CD, and *trans*-polydatin-HP-β-CD complexes was decreased for 42%, 36% and 28%, respectively. These results showed that the complexation of *trans*-polydatin with CDs led to an increase in the *trans*-polydatin photostability during the exposure to UV radiation. This finding is consistent with previous study.^{39,40} Therefore, *trans*-polydatin was highly protected against photoisomerization by inclusion complexation.

Antioxidant activity of polydatin in free and complex form

The reducing power is a sensible evidence for the antioxidant activity of an extract or a compound.^{41,42} In the reducing power assay, the Fe^{3+} /ferricyanide complex was reduced to the Fe^{2+} ions by the presence of antioxidants. The reducing reaction can be monitored spectrophotometrically by recording the






Fig. 8 The photoisomerization of *trans*-polydatin in the absence and presence of β -CD, Me- β -CD and HP- β -CD.

absorbance at 700 nm. According to the mentioned principle, the higher absorbance value at 700 nm represent a stronger reducing power of the reaction compound.

Fig. 9 shows a comparison of the reducing power values of *trans*-polydatin ($p < 0.05$), *trans*-polydatin- β -CD ($p < 0.05$), *trans*-polydatin-Me- β -CD ($p < 0.05$), and *trans*-polydatin-HP- β -CD ($p < 0.05$) complexes. The reducing powers values of the four samples were all enhanced along with the increasing concentration among the tested range, but the reducing power values of the three inclusion complexes were stronger than that native *trans*-polydatin. Since this assay was carried out in an aqueous solution, the hydrophobic and assembled *trans*-polydatin molecules could not fully close and react with the Fe^{3+} /ferricyanide ions in the test. However, the complexation made the *trans*-polydatin was totally dissolved in water. Thus, the reducing power of the three inclusion complexes was stronger than that of native *trans*-polydatin. Additionally, the reducing power order of the different inclusion complex is *trans*-polydatin-HP- β -CD > *trans*-polydatin-Me- β -CD > *trans*-polydatin- β -CD.




Fig. 9 Reduce powers of *trans*-polydatin, *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex.




Fig. 10 DPPH radical scavenging activities of the *trans*-polydatin, *trans*-polydatin- β -CD, *trans*-polydatin-Me- β -CD, and *trans*-polydatin-HP- β -CD inclusion complex.

Fig. 10 shows a comparison of the DPPH radical-scavenging activity of *trans*-polydatin ($p < 0.05$), *trans*-polydatin- β -CD ($p < 0.05$), *trans*-polydatin-Me- β -CD ($p < 0.05$), and *trans*-polydatin-HP- β -CD complexes ($p < 0.05$). As can be seen, after complexation with CDs, the scavenging ability of *trans*-polydatin increased significantly. The order is *trans*-polydatin-HP- β -CD > *trans*-polydatin-Me- β -CD > *trans*-polydatin- β -CD, which indicates that the *trans*-polydatin-CDs complexes have stronger DPPH radical-scavenging ability than native *trans*-polydatin. The DPPH scavenging ability of the antioxidant is closely related to its hydrogen-donating ability.^{43,44} The increasing DPPH scavenging ability of *trans*-polydatin could be attributed to the enhancement of its hydrogen-donating ability, caused by the complexation of CDs. When *trans*-polydatin is complexed with CDs, one or more intermolecular hydrogen bonds form between *trans*-polydatin and the CDs. This weakens the intramolecular hydrogen bonds of *trans*-polydatin. Ultimately, the hydrogen-donating ability of *trans*-polydatin is improved. The stronger interaction between *trans*-polydatin and HP- β -CD weakened the covalent bonds between hydrogen and oxygen in the hydroxyl groups, which in turn improved the hydrogen donation of the hydroxyl groups of *trans*-polydatin. In contrast, the multiple methyl group substitutions of Me- β -CD impaired the hydrogen-bonding interaction between *trans*-polydatin and Me- β -CD. This is unfavorable to the hydrogen-donating ability of *trans*-polydatin. Ultimately, the DPPH scavenging ability of *trans*-polydatin-HP- β -CD is stronger than that of *trans*-polydatin-Me- β -CD, which is consistent with the binding ability of the three CDs. Therefore, we can conclude that the antioxidant property of *trans*-polydatin-CDs is closely related their mode of binding. Additionally, the effective stabilization of radical species in the CDs cavity also plays an important role in the scavenging activity of DPPH free radical. The similar results were also found for canthaxanthin and canthaxanthin/HP- β -CD complex.^{45,46}



Conclusions

The inclusion complexes of *trans*-polydatin with β -CD, Me- β -CD and HP- β -CD were prepared and characterized by phase-solubility, XRD, DSC, SEM, ^1H NMR, 2D NMR, photostability and antioxidant studies. The phase-solubility, XRD, DSC, SEM, ^1H NMR and 2D NMR studies confirmed that *trans*-polydatin can form the inclusion complexes with three kinds of CDs, and the ratio between the host-guest molecules is 1 : 1. Furthermore, the solubility and thermal stability of *trans*-polydatin was improved due to the formation of inclusion complex. The ^1H -NMR and 2D ROESY analyses showed that the aromatic ring of *trans*-polydatin was the part that inserted into the cavity of CDs, thus forming an inclusion complex. The photostability of *trans*-polydatin was enhanced after encapsulating by CDs. Antioxidant activity studies showed that the antioxidant performance of the inclusion complexes was better than the native *trans*-polydatin, and *trans*-polydatin-HP- β -CD inclusion complex was the most effective form. Given the easy preparation and environmentally friendly process of *trans*-polydatin-CDs inclusion complexes, it is a promising way to design a novel formulation of *trans*-polydatin for its drug bioavailability or phytochemical preparations.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work is financially supported by the National Natural Science Foundation of China (31501445).

References

- W. W. Xing, J. Z. Wu, M. Jia, J. Du, H. Zhang and L. P. Qin, *Biomed. Pharmacother.*, 2009, **63**, 457–462.
- L. Yang, Y. Sun and G. Huang, *Int. J. Biol. Macromol.*, 2018, **111**, 780.
- H. Zhang, *Pharm. Biol.*, 2013, **51**, 1347–1354.
- C. W. Shan, *Acta Pharm. Sin.*, 1988, **23**, 394–396.
- H. Li, B. Shi, Y. Li and F. Yin, *J. Biochem. Mol. Toxicol.*, 2017, **31**, e21900.
- Z. Kerem, I. Bilkis, M. A. Flaishman and L. Sivan, *J. Agric. Food Chem.*, 2006, **54**, 1243–1247.
- H. Qiao, H. Chen, Y. Dong, H. Ma, G. Zhao, F. Tang and Z. Li, *Oxid. Med. Cell. Longevity*, 2016, **2016**, 5139458.
- X. Xie, J. Peng, K. Huang, J. Huang, X. Shen, P. Liu and H. Huang, *Mol. Cell. Endocrinol.*, 2012, **362**, 183–193.
- A. A. Bertelli, F. Ferrara, G. Diana, A. Fulgenzi, M. Corsi, W. Ponti, M. E. Ferrero and A. Bertelli, *Int. J. Tissue React.*, 1999, **21**, 93–104.
- S. Fabris, F. Momo, G. Ravagnan and R. Stevanato, *Biophys. Chem.*, 2008, **135**, 76–83.
- S. Mathew, M. Hedström and P. Adlercreutz, *Process Biochem.*, 2012, **47**, 528–532.
- J. Szejtli, *Chem. Rev.*, 1998, **98**, 1743–1754.
- J. G. Galvão, V. F. Silva, S. G. Ferreira, F. R. M. França, D. A. Santos, L. S. Freitas, P. B. Alves, A. A. S. Araújo, S. C. H. Cavalcanti and R. S. Nunes, *Thermochim. Acta*, 2015, **608**, 14–19.
- D. Leonardi, M. E. Bombardiere and C. J. Salomon, *Int. J. Biol. Macromol.*, 2013, **62**, 543–548.
- O. I. Maloletkina, K. A. Markossian, R. A. Asryants, P. I. Semenyuk, V. F. Makeeva and B. I. Kurganov, *Int. J. Biol. Macromol.*, 2010, **46**, 487–492.
- J. Wang, W. Li, H. Yu, Z. U. Abdin, Y. Chen, Q. Chen, W. Zhou, H. Zhang and C. Xiao, *Int. J. Biol. Macromol.*, 2016, **88**, 333–344.
- Y. Wei, J. Zhang, Y. Zhou, W. Bei, Y. Li, Q. Yuan and H. Liang, *Carbohydr. Polym.*, 2017, **159**, 152.
- D. Duchêne, A. Bochot and T. Loftsson, *STP Pharma Prat.*, 2009, **19**, 15–27.
- H. M. C. Marques, A. C. Figueiredo and M. G. Miguel, *Flavour Fragrance J.*, 2010, **25**, 313–326.
- J. Carlstedt, A. González-Pérez, M. Alatorre-Meda, R. S. Dias and B. Lindman, *Int. J. Biol. Macromol.*, 2010, **46**, 153–158.
- M. Terauchi, T. Inada, A. Tonegawa, A. Tamura, S. Yamaguchi, K. Harada and N. Yui, *Int. J. Biol. Macromol.*, 2016, **93**, 1492–1498.
- S. An, J. He, L. Sun, D. Ren and Y. Ban, *J. Mol. Struct.*, 2013, **1037**, 9–14.
- B. Liu, Y. Li, H. Xiao, Y. Liu, H. Mo, H. Ma and G. Liang, *J. Food Sci.*, 2015, **80**, C1156–C1161.
- J. Q. Zhang, K. M. Jiang, X. G. Xie, Y. Jin and J. Lin, *J. Mol. Liq.*, 2016, **219**, 592–598.
- X. H. Li, Z. Y. Jin and J. Wang, *Food Chem.*, 2007, **103**, 461–466.
- T. Higuchi and K. A. Connors, *Adv. Anal. Chem. Instrum.*, 1965, **4**, 117–212.
- S. Ma, Z. Zhao and P. Liu, *J. Food Meas. Charact.*, 2018, 1–11.
- T. Hatano, H. Kagawa, T. Yasuhara and T. Okuda, *Chem. Pharm. Bull.*, 1988, **36**, 2090–2097.
- S. E. Çelik, M. Özyürek, K. Güçlü and R. Apak, *J. Inclusion Phenom. Macrocyclic Chem.*, 2015, **83**, 309–319.
- Q. F. Zhang, H. C. Nie, X. C. Shangguang, Z. P. Yin, G. D. Zheng and J. G. Chen, *J. Agric. Food Chem.*, 2013, **61**, 151–156.
- Z. Aytac, S. Ipek, E. Durgun and T. Uyar, *J. Mater. Sci.*, 2018, **53**, 1527–1539.
- A. Celebioglu and T. Uyar, *J. Agric. Food Chem.*, 2017, **65**, 5404.
- A. M. Dias, S. D. G. Da, Â. M. Fiorentini, V. Z. Pinto, L. T. Lim, R. Z. E. Da and D. Arg, *Int. J. Biol. Macromol.*, 2017, **104**, 874.
- L. P. N. De, S. D. D. Da, V. G. Costa, D. Q. Falcão and D. L. A. Kg, *Food Chem.*, 2016, **208**, 124–131.
- T. Pralhad and K. Rajendrakumar, *J. Pharm. Biomed. Anal.*, 2004, **34**, 333–339.
- S. Zidane, A. Maiza, H. Bouleghlem, W. Herizi and S. Dahmani, 2016.
- H. J. Schneider, F. Hacket, V. Rüdiger and H. Ikeda, *Chem. Rev.*, 1998, **98**, 1755.
- K. Srinivasan and T. Stalin, *Spectrochim. Acta, Part A*, 2014, **130**, 105–115.



- 39 S. Dong, Y. Huang, R. Zhang, Z. Lian, S. Wang and Y. Liu, *Eur. J. Lipid Sci. Technol.*, 2014, **116**, 978–986.
- 40 I. Savic-Gajic, I. M. Savic, V. D. Nikolic, L. B. Nikolic, M. M. Popsavin and A. J. Kapor, *J. Inclusion Phenom. Macrocyclic Chem.*, 2016, **86**, 1–11.
- 41 K. L. Yap, X. Liu, J. C. Thenmozhiyal and P. C. Ho, *Eur. J. Pharm. Sci.*, 2005, **25**, 49–56.
- 42 B. Liu, M. A. Yuxiang, C. Yuan, S. U. Caijuan, H. U. Lizhi and J. Wang, *J. Food Biochem.*, 2012, **36**, 634–641.
- 43 A. Corciova, C. Ciobanu, A. Poiata, C. Mircea, A. Nicolescu, M. Drobot, C. D. Varganici, T. Pinteala and N. Marangoci, *Dig. J. Nanomater. Biostruct.*, 2014, **9**, 1623–1637.
- 44 Q. Li, H. Pu, P. Tang, B. Tang, Q. Sun and H. Li, *Food Chem.*, 2017, **245**, 1062–1069.
- 45 M. Strazisar, S. Andresek and A. Smidovnik, *Food Chem.*, 2008, **110**, 636–642.
- 46 C. Jullian, T. Orosteguis, F. P'erez-Cruz, P. Sanchez, F. Mendizabal and C. Olea-Azar, *Spectrochim. Acta, Part A*, 2008, **71**, 269–275.

